Alpha Healthcare Acquisition Corp. III focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in New York, New York.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the successful completion of its business combination (the "Business Combination") with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications ("Carmell"). The resulting combined company, Carmell Therapeutics Corporation, is expected to commence trading of its shares of common stock and warrants on the Nasdaq Capital Market® under the ticker symbols "CTCX" and "CTCXW," respectively, on July 17, 2023.
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a non-binding letter of intent (the "LOI") to acquire a commercial stage regenerative medicine company (the "Target") conditioned upon the closing of ALPA's initial business combination with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications ("Carmell"). ALPA has set a Stockholders Meeting (the "Meeting") to consider the previously announced business combination with Carmell for J
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a definitive business combination agreement with Carmell Therapeutics Corporation ("Carmell™"), a Phase 2-stage biotechnology platform company developing allogeneic plasma-based biomaterials for bone and soft tissue healing indications. Upon closing of the transaction, ALPA will be renamed Carmell Therapeutics Corporation (the "Combined Company"). Mr. Shukla will serve as Chairman and Mr. Randy Hubbell will serve as Chief Executive Officer of the Combined Company. The Combined Company's common stock is expected to be listed on the Na
SC 13G/A - Carmell Corp (0001842939) (Subject)
SC 13G/A - Carmell Corp (0001842939) (Subject)
SC 13G - Carmell Corp (0001842939) (Subject)
SC 13G/A - Carmell Corp (0001842939) (Subject)
SC 13G/A - Carmell Corp (0001842939) (Subject)
SC 13G/A - Carmell Corp (0001842939) (Subject)
SC 13G/A - Carmell Corp (0001842939) (Subject)
SC 13G - Carmell Corp (0001842939) (Subject)
SC 13G/A - Carmell Corp (0001842939) (Subject)
SC 13G - Carmell Corp (0001842939) (Subject)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
8-K - Carmell Corp (0001842939) (Filer)
8-K - Carmell Corp (0001842939) (Filer)
8-K - Carmell Corp (0001842939) (Filer)
8-K/A - Carmell Corp (0001842939) (Filer)
8-K/A - Carmell Corp (0001842939) (Filer)
8-K - Carmell Corp (0001842939) (Filer)
8-K - Carmell Corp (0001842939) (Filer)
NT 10-Q - Carmell Corp (0001842939) (Filer)
8-K/A - Carmell Corp (0001842939) (Filer)
8-K - Carmell Corp (0001842939) (Filer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a non-binding letter of intent (the "LOI") to acquire a commercial stage regenerative medicine company (the "Target") conditioned upon the closing of ALPA's initial business combination with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications ("Carmell"). ALPA has set a Stockholders Meeting (the "Meeting") to consider the previously announced business combination with Carmell for Jul
Transaction Overview Under the terms of the proposed transaction, Carmell's shareholders will receive an aggregate of 15 million shares of ALPA's Class A common stock (the "Class A Shares") in exchange for their existing Carmell shares, as contemplated by the terms of the business combination agreement. Assuming that no ALPA shareholders elect to redeem their shares, the market capitalization of the Combined Company will be approximately $328 million and it is estimated that the current shareholders of Carmell will own approximately 46% of the issued and outstanding shares in the Combined Company at closing. The Combined Company is expected to receive gross proceeds of approximately $154 mi
-SEC Filing
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a new 52-week low. Tenax Therapeutics (NASDAQ:TENX) was the smallest company when considering market cap to set a new 52-week low. Esports Entertainment (NASDAQ:GMBL) was the biggest loser of the morning session, as it dropped 34.48% to reach its new 52-week low. Morgan Stanley Emerg Mkts (NYSE:MSD) shares were the most resilient of the group, as shares actually moved up 0.58% in response to hitting its 52-week low. The following stocks achieved new 52-week lows during the first half-hour of trading on Monday: Gi